Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations.

Human pathology - 1 Aug 2016

Holck Susanne, Bonde Jesper, Pedersen Helle, Petersen Anja Alex, Chaube Amita, Nielsen Hans Jørgen, Larsson Lars-Inge

Abstract excerpt

Colorectal cancers (CRC) often show activating mutations of the KRAS or BRAF genes, which stimulate the extracellular signal-regulated kinase (ERK) pathway, thus increasing cell proliferation and inhibiting apoptosis. However, immunohistochemical results on ERK activation in such tumors differ greatly. Recently, using a highly optimized immunohistochemical method, we obtained evidence that high levels of ERK...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to Caco-2 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Activation

Share to Mitogen-Activated Protein Kinase 1

Share to Mitogen-Activated Protein Kinase 3

Share to Predictive Value of Tests

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 27036313
DOI: 10.1016/j.humpath.2016.03.001

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations.PMID 27036313Read ↗

ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics.Semantic proximity Read ↗

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.Semantic proximity Read ↗

Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations.Semantic proximity Read ↗

Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis.Semantic proximity Read ↗

Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy.Semantic proximity Read ↗

Clinical-pathological correlation of K-Ras mutation and ERK phosphorylation in colorectal cancer.Semantic proximity Read ↗

High nuclear expression of phosphorylated extracellular signal-regulated kinase in tumor cells in colorectal glands is associated with poor outcome in colorectal cancer.Semantic proximity Read ↗

Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition.Semantic proximity Read ↗

High Erk activity suppresses expression of the cell cycle inhibitor p27Kip1 in colorectal cancer cellsSemantic proximity Read ↗

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.Semantic proximity Read ↗

Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.Semantic proximity Read ↗

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.